Compound: neomycin
SMILES: O1[C@H](O[C@H]2[C@H](O[C@@H]3O[C@H](CO)[C@H]([C@H]3O)O[C@H]4O[C@H]([C@@H](O)[C@@H]([C@H]4N)O)CN)[C@@H](O)[C@H](N)C[C@@H]2N)[C@H](N)[C@@H](O)[C@@H]([C@H]1CN)O
InChIKey: PGBHMTALBVVCIT-VCIWKGPPSA-N
Synonyms: neomycin, Fradiomycin, Neomas, Nivemycin, Myacyne, Neolate, 1404-04-2, Caswell No. 595, Vonamycin powder V, Neomin, Neomicina, Neomycine, Neomycinum, PIMAVECORT, (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol, I16QD7X297, VONAMYCIN, Kaomycine, Neomycin Complex, (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-((1R,2R,3S,4R,6S)-4,6-diamino-2-((2S,3R,4S,5R)-4-((2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl)oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl)oxy-3-hydroxycyclohexyl)oxyoxane-3,4-diol, RefChem:55694, CHEBI:7507, DTXSID9041073, A01AB08, A07AA01, B05CA09, D06AX04, J01GB05, R02AB01, S01AA03, S02AA07, S03AA01, 215-766-3, Framycetin, NEOMYCIN B, 119-04-0, Soframycin, Actilin, Framygen, Fradiomycin B, Enterfram, Framicetina, Framycetine, Fradiomycinum, Framycetinum, Antibiotic 10676, Neobrettin, Actiline, CCRIS 5462, Framidal, Framycin, Francetin, Dekamycin iii, HSDB 3242, Soframycine, Framycetin (INN), Neomycin B Hexaacetate, ANTIBIOTIQUE EF 185, Neomcin, 4BOC774388, (1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-alpha-D-glucopyranoside, Neomicina [DCIT], Framycetinum [INN-Latin], Bycomycin, FRAMYCETIN [INN], Neomycine [INN-French], Neomycinum [INN-Latin], (2S,3S,4R,5R,6R)-5-Amino-2-(aminomethyl)-6-(((2R,3S,4R,5S)-5-(((1R,2R,3S,5R,6S)-3,5-diamino-2-(((2R,3R,4R,5S,6R)-3-amino-6-(aminomethyl)-4,5-dihydroxytetrahydro-2H-pyran-2-yl)oxy)-6-hydroxycyclohexyl)oxy)-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl)oxy)tetrahydro-2H-pyran-3,4-diol, Framycetine [INN-French], NMY, Framicetina [INN-Spanish], Framycetin [INN:BAN:DCF], Jernadex, Neomycin Trisulfate Hydrate Deuterated, Fradiomycin Trisulfate Hydrate deuterated, (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxy-tetrahydropyran-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]oxy-3-hydroxy-cyclohexoxy]tetrahydropyran-3,4-diol, 11004-65-2, Fradiomycin B;Neomycin B, Neomycin [INN:BAN], C23H46N6O13, EINECS 204-292-2, EINECS 215-766-3, EPA Pesticide Chemical Code 006303, BRN 0101621, Mycerin, UNII-I16QD7X297, Actilin;, UNII-4BOC774388, Neomycin B;, Antibiotic 956, Neomycin B Acetate, Antibiotic produced by Streptomyces decaris. Neomycin B, NEOMYCIN B [MI], Prestwick3_000158, Neomycin B; Fradiomycin B, SCHEMBL3279, FRAMYCETIN [WHO-DD], BSPBio_000296, GTPL709, NEOMYCIN B [USP-RS], 4-18-00-07476 (Beilstein Handbook Reference), BPBio1_000326, CHEBI:7508, CHEMBL184618, orb1707294, DTXSID2023359, y)tetrahydro-2H-pyran-3,4-diol, GLXC-10574, HMS2089P15, EBC-27391, MFCD09788228, AKOS024284361, CS-6390, DB00452, NCGC00179612-01, D-Streptamine, O-2,6-diamino-2,6-dideoxy-.beta.-L-idopyranosyl-(1.->3)-O-.beta.-D-ribofuranosyl-(1->5)]-O-[2,6-diamino-2,6-dideoxy-.alpha.-D-glucopyranosyl-(1->4)]-2-deoxy, D-Streptamine, O-2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1-4)-O-(O-2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl-(1-3)-beta-D-ribofuranosyl-(1-5))-2-deoxy-, DA-63612, FN175622, HY-17624, ST075177, AB00443887, NS00072944, C01737, D05140, AB00443887-03, EN300-7480789, MYCIFRADIN; NEOMAS; PIMAVECORT; VONAMYCIN, ANTIBIOTIC PRODUCED BY STREPTOMYCES DECARIS, Q4492348, BRD-K71013094-001-02-5, BRD-K71013094-065-01-2, BRD-K71013094-326-01-8, (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-{[(1R,2R,3S,4R,6S)-4,6-diamino-2-{[(2S,3R,4S,5R)-4-{[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy}-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-3-hydroxycyclohexyl]oxy}oxane-3,4-diol, (2S,3S,5R,6R)-5-amino-2-(aminomethyl)-6-(((2R,3S,4R,5S)-5-(((1R,2R,3S,5R,6S)-3,5-diamino-2-(((2R,3R,4R,5S,6R)-3-amino-6-(aminomethyl)-4,5-dihydroxytetrahydro-2H-pyran-2-yl)oxy)-6-hydroxycyclohexyl)oxy)-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl)oxy)tetrahydro-2H-pyran-3,4-diol, 6-(2-{(4S,2R,3R,5R)-4-[(5S,6S,2R,3R,4R)-3-amino-6-(aminomethyl)-4,5-dihydroxy( 2H-3,4,5,6-tetrahydropyran-2-yloxy)]-3-hydroxy-5-(hydroxymethyl)oxolan-2-yloxy }(3S,6S,1R,2R,4R)-4,6-diamino-3-hydroxycyc, 6-(2-{(4S,2R,3R,5R)-4-[(5S,6S,2R,3R,4R)-3-amino-6-(aminomethyl)-4,5-dihydroxy( 2H-3,4,5,6-tetrahydropyran-2-yloxy)]-3-hydroxy-5-(hydroxymethyl)oxolan-2-yloxy }(3S,6S,1R,2R,4R)-4,6-diamino-3-hydroxycyclohexyloxy)(3S,2R,4R,5R,6R)-5-amino- 2-(aminomethyl)-2H, D-STREPTAMINE, O-2,6-DIAMINO-2,6-DIDEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->4)-O-(O-2,6-DIAMINO-2,6-DIDEOXY-.BETA.-L-IDOPYRANOSYL-(1->3)-.BETA.-D-RIBOFURANOSYL-(1->5))-2-DEOXY-, D-STREPTAMINE, O-2,6-DIAMINO-2,6-DIDEOXY-.BETA.-L-IDOPYRANOSYL-(1->3)-O-.BETA.-D-RIBOFURANOSYL-(1->5)-O-(2,6-DIAMINO-2,6-DIDEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->4))-2-DEOXY-, lohexyloxy)(3S,2R,4R,5R,6R)-5-amino- 2-(aminomethyl)-2H-3,4,5,6-tetrahydropyran-3,4-diol
Theoretical properties:
molecular_formula: C23H46N6O13
molecular_weight: 614.6 g/mol
exact_mass: 614.31228554 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 13
hydrogen_bond_acceptor_count: 19
rotatable_bond_count: 9
heavy_atom_count: 42
topological_polar_surface_area: 353 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
melting_point: 6 °C (sulfate form)
solubility: Soluble in water ... solutions up to 250 mg/mL may be prepared
Descriptions:
pubchem: Framycetin is a tetracyclic antibacterial agent derived from neomycin, being a glycoside ester of neamine and neobiosamine B. It has a role as an antibacterial drug, an allergen and an Escherichia coli metabolite. It is a conjugate base of a framycetin(6+).
chebi: A tetracyclic antibacterial agent derived from neomycin, being a glycoside ester of neamine and neobiosamine B.
chembl: FRAMYCETIN is a small molecule listed in the ChEMBL database and has reached clinical trial phase 3.0.
wikipedia: Neomycin, also known as framycetin, is an aminoglycoside antibiotic that displays bactericidal activity against Gram-negative aerobic bacilli and some anaerobic bacilli where resistance has not yet arisen. It is generally not effective against Gram-positive bacilli and anaerobic Gram-negative bacilli. Neomycin comes in oral and topical formulations, including creams, ointments, and eyedrops. Neomycin belongs to the aminoglycoside class of antibiotics that contain two or more amino sugars connected by glycosidic bonds.
Neomycin was discovered in 1949 by microbiologist Selman Waksman and his student Hubert Lechevalier at Rutgers University.  Neomycin received approval for medical use in 1952. Rutgers University was granted the patent for neomycin in 1957.